Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma

Schmidinger, Manuela; Wenzel, Catharina; Locker, Gottfried J.; Muehlbacher, Ferdinand; Steininger, R.; Gnant, Michael; Crevenna, Richard; Budinsky, Alexandra C.

doi:10.1054/bjoc.2001.2149

Cited by 33 publications

(15 citation statements)

References 26 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The difficulty in relying on response rate as a marker of activity was further illustrated by Hong and Tseng (2003): despite 10% of patients responding to treatment and a further 33% achieving stable disease, the median survival was only 3 months. A favourable toxicity profile has been consistent across all the HCC studies (Halm et al, 2000;Ruff et al, 2001;Schmidinger et al, 2001;Miller et al, 2002;Hong and Tseng, 2003). We found few grade 3 -4 toxicities and notably none involving palmar-plantar erythrodysaesthesia, a dose-limiting toxicity seen in early studies along with stomatitis and neutropaenia (Muggia et al, 1997;Ranson et al, 1997).…”

Section: Discussionmentioning

confidence: 59%

“…A number of studies contemporary to ours (see Table 3) have shown, at best, response rates of 10 -17% (Ruff et al, 2001;Schmidinger et al, 2001;Hong and Tseng, 2003). Two studies, as in our case, revealed no responses: in the first, no objective responses were seen in 16 patients receiving 30 -40 mg m À2 three-weekly.…”

Section: Discussionmentioning

confidence: 60%

“…Miller et al (2002) reached the same conclusion with a 0% response rate in a mixed study of 10 HCC (and eight cholangiocarcinoma) patients. Based on a median survival of 1-year, Schmidinger et al (2001) concluded that PLD warranted further studies. However, Ruff et al (2001) who demonstrated a 17% response rate achieved a median survival of only 5.3 months.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In the midst of systemic treatment modalities for advanced HCC, doxorubicin (C 27 H 29 NO 11 ·HCl; 579.99 Da) has been the one most extensively investigated for HCC treatment [9,10,11,12,13]; nevertheless, systemic doxorubicin has not turned out to be a standard treatment care for HCC owing to its severe systemic toxicity. It is in general consensus that targeting drugs specifically to the tumor site may play role in navigating their undesirable manifestations.…”

Section: Nanodoxorubicinmentioning

confidence: 99%

Nano-Sized Drug Delivery Systems: Development and Implication in Treatment of Hepatocellular Carcinoma

Badrealam

Owais²

2015

Dig Dis

View full text Add to dashboard Cite

Liver cancer results in enormous human toll worldwide. Over the years, various chemotherapeutic entities have been employed for treatment of advanced HCC; however, as of yet none embody attributes to improve overall survival. Following rapid advancement in nanotechnology, it is envisage that nanoscale systems may emerge as intriguing platforms to improve chemotherapeutic strategies against various cancers including liver cancer; with better insight in the understanding of pathophysiology of liver cancer and material science, the field of nanotechnology may bring newer hope to liver cancer treatment. Reckoning with these, we detailed the arsenal of nanoformulations that are in various stages of clinical development/ preclinical settings for the treatment of liver cancer together with providing a glimpse of the attributes of nanotechnology in revolutionizing the status of chemotherapeutic modalities.

show abstract

“…Objective responses to doxorubicin have generally been about 10% with an associated short median survival. [35][36][37][38][39][40] Limited data from trials with epirubicin suggest better response rates but not necessarily longer survival. 41,42 A variety of phase II studies with an anthracycline combined with another agent have not led to a consistent improvement in outcome compared to single-agent studies.…”

Section: Systemic Treatmentmentioning

confidence: 99%

Cancer of the Liver and Bile Ducts

Kendrick

Grambihler²,

Gores

et al.

Oncology

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in the world and the third most common cause of cancer death worldwide.1 More than 500,000 deaths per year are attributed to HCC, representing 10% of all deaths from cancer. In select areas of Asia and Africa, HCC is the most common cause of death due to cancer. The incidence in Europe and the United States is relatively low but is increasing. In Europe, HCC is now the leading cause of death among patients with cirrhosis.2 In the United States, epidemiologic studies have demonstrated a doubling of HCC incidence over the past two decades.3 This increase, which has been attributed to the increasing prevalence of chronic hepatitis C virus (HCV) infection, is expected to continue over the next two decades, given the lag time between the onset of chronic hepatitis and development of HCC. EtiologyUnique among many other cancers, HCC has well-defined major risk factors. Cirrhosis is the strongest predisposing factor for development of HCC, present in 80% of patients. Chronic viral infection is the most frequent major risk factor for development of HCC. In Asia and Africa, hepatitis B viral (HBV) infection is common, whereas in the West and Japan, hepatitis C virus (HCV) is the main risk factor. The association of HCC and HBV infection is one of the most well recognized etiologic relationships in cancer biology. 4 In epidemiologic studies, the prevalence of HBV carriers correlates with incidence of HCC. Chronic HBV carriers have a 100-fold relative risk of developing HCC compared with noncarriers. 5Up to 40% of HBV carriers who develop HCC do not have evidence of cirrhosis, demonstrating the direct carcinogenic potential of HBV infection.6 Prevention of HBV infection reduces the incidence of HCC, as demonstrated in Taiwan, where vaccination of infants reduced the incidence of HBV carriers and simultaneously decreased the incidence of HCC by 60% compared with nonimmunized children. 7,8 In developed countries, HCC arises in cirrhotic livers as a result of HCV infection or excessive alcohol intake. Approximately 170 million people are infected with HCV.9 Vaccination for prevention of HCV infection is currently not available. Prevention is focused on preventing transmission by transfusion of blood products and in halting the progression of infected individuals to cirrhosis by antiviral regimens such as pegylated interferon and ribavirin. Cirrhosis independent of the etiology is thought in most instances to increase the risk of HCC. The degree of association between cirrhosis and HCC, however, is dependent on the primary condition. Cirrhosis from HCV, HBV, alcohol abuse, and hemochromatosis portends a greater risk for HCC than other conditions such as autoimmune hepatitis, primary biliary cirrhosis, a 1 -antitrypsin deficiency, and Wilson's disease, where HCC is uncommon.10

show abstract

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma

Cited by 33 publications

References 26 publications

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

Nano-Sized Drug Delivery Systems: Development and Implication in Treatment of Hepatocellular Carcinoma

Cancer of the Liver and Bile Ducts

Contact Info

Product

Resources

About